Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study)
Hiroshi Matsuoka, Takeshi Yamada, Ryo Ohta, Yoichiro Yoshida, Tatsuyuki Watanabe, Makoto Takahashi, Chihiro Kosugi, A. Fukazawa, Hidekazu Kuramochi, Akihisa Matsuda, Hiromichi Sonoda, Hiroshi Yoshida, Suguru Hasegawa, Kazuhiro Sakamoto, Toshiaki Otsuka, Keiji Hirata, Keiji Koda, the TAS CC4 Study Group
Topics & Concepts
MedicineBevacizumabNeutropeniaInternal medicineClinical endpointColorectal cancerAdverse effectChemotherapyProgression-free survivalPhases of clinical researchLeukopeniaFebrile neutropeniaSurgical oncologyOncologySurgeryClinical trialCancerColorectal Cancer Treatments and StudiesColorectal Cancer Surgical TreatmentsProtease and Inhibitor Mechanisms